Red X iconGreen tick iconYellow tick icon

Peter Chapman

BSc, M.D(Otago) FRACP, PGDipMSM(Otago)


Peter is a Rheumatologist and Clinical Director of Department of Rheumatology, Immunology and Allergy, Canterbury District Health Board.

He has a broad range of interests in Rheumatology and is involved in undergraduate and postgraduate education.


Stamp, L., Horne, A., Mihov, B., Drake, J., Haslett, J., Chapman, P. T., Frampton, C., & Dalbeth, N. (2023). Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Annals of the Rheumatic Diseases, 82, 1626-1634. doi: 10.1136/ard-2023-224731

Lyne, S. A., Ruediger, C., Lester, S., Chapman, P. T., Shanahan, E. M., Hill, C. L., & Stamp, L. (2022). Giant cell arteritis: A population-based retrospective cohort study exploring incidence and clinical presentation in Canterbury, Aotearoa New Zealand. Frontiers in Medicine, 9, 1057917. doi: 10.3389/fmed.2022.1057917

Li, B., Falvey, J., Pike, L., Sies, C., Chapman, P., & Florkowski, C. (2022). A case of macroenzyme aspartate aminotransferase (macro-AST) in a patient with seronegative rheumatoid arthritis. New Zealand Medical Journal, 135(1558), 106-109. Retrieved from

Monti, S., Craven, A., Klersy, C., Montecucco, C., Caporali, R., Watts, R., … on behalf of DCVAS Collaborators, including Chapman, P. T. (2021). Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes. Rheumatology, 60(2), 617-628. doi: 10.1093/rheumatology/keaa215

Stamp, L. K., & Chapman, P. T. (2020). Allopurinol hypersensitivity: Pathogenesis and prevention. Best Practice & Research: Clinical Rheumatology, 34, 101501. doi: 10.1016/j.berh.2020.101501

Back to top